116 related articles for article (PubMed ID: 38161319)
1. Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial.
McKay RR; Xie W; Yang X; Acosta A; Rathkopf D; Laudone VP; Bubley GJ; Einstein DJ; Chang P; Wagner AA; Kane CJ; Preston MA; Kilbridge K; Chang SL; Choudhury AD; Pomerantz MM; Trinh QD; Kibel AS; Taplin ME
Cancer; 2024 May; 130(9):1629-1641. PubMed ID: 38161319
[TBL] [Abstract][Full Text] [Related]
2. Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.
McKay RR; Xie W; Ye H; Fennessy FM; Zhang Z; Lis R; Calagua C; Rathkopf D; Laudone VP; Bubley GJ; Einstein DJ; Chang PK; Wagner AA; Parsons JK; Preston MA; Kilbridge K; Chang SL; Choudhury AD; Pomerantz MM; Trinh QD; Kibel AS; Taplin ME
J Urol; 2021 Jul; 206(1):80-87. PubMed ID: 33683939
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.
Fleshner NE; Sayyid RK; Hansen AR; Chin JLK; Fernandes R; Winquist E; van der Kwast T; Sweet J; Lajkosz K; Kenk M; Hersey K; Veloso R; Berlin D; Herrera-Caceres JO; Sridhar S; Moussa M; Finelli A; Hamilton RJ; Kulkarni GS; Zlotta AR; Joshua AM
Clin Cancer Res; 2023 Oct; 29(19):3867-3874. PubMed ID: 37439809
[TBL] [Abstract][Full Text] [Related]
4. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
McKay RR; Ye H; Xie W; Lis R; Calagua C; Zhang Z; Trinh QD; Chang SL; Harshman LC; Ross AE; Pienta KJ; Lin DW; Ellis WJ; Montgomery B; Chang P; Wagner AA; Bubley GJ; Kibel AS; Taplin ME
J Clin Oncol; 2019 Apr; 37(11):923-931. PubMed ID: 30811282
[TBL] [Abstract][Full Text] [Related]
6. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Taplin ME; Montgomery B; Logothetis CJ; Bubley GJ; Richie JP; Dalkin BL; Sanda MG; Davis JW; Loda M; True LD; Troncoso P; Ye H; Lis RT; Marck BT; Matsumoto AM; Balk SP; Mostaghel EA; Penning TM; Nelson PS; Xie W; Jiang Z; Haqq CM; Tamae D; Tran N; Peng W; Kheoh T; Molina A; Kantoff PW
J Clin Oncol; 2014 Nov; 32(33):3705-15. PubMed ID: 25311217
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
Autio KA; Antonarakis ES; Mayer TM; Shevrin DH; Stein MN; Vaishampayan UN; Morris MJ; Slovin SF; Heath EI; Tagawa ST; Rathkopf DE; Milowsky MI; Harrison MR; Beer TM; Balar AV; Armstrong AJ; George DJ; Paller CJ; Apollo A; Danila DC; Graff JN; Nordquist L; Dayan Cohn ES; Tse K; Schreiber NA; Heller G; Scher HI
Eur Urol Open Sci; 2021 Dec; 34():70-78. PubMed ID: 34934969
[TBL] [Abstract][Full Text] [Related]
8. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
[TBL] [Abstract][Full Text] [Related]
9. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
Parikh NR; Huiza C; Patel JS; Tsai S; Kalpage N; Thein M; Pitcher S; Lee SP; Inouye WS; Jordan ML; Sanati H; Jafari L; Bennett CJ; Gin GE; Kishan AU; Reiter RE; Lewis M; Sadeghi A; Aronson WJ; Garraway IP; Rettig MB; Nickols NG
BMC Cancer; 2019 Apr; 19(1):291. PubMed ID: 30935383
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
Spetsieris N; Boukovala M; Alafis I; Davis J; Zurita A; Wang X; Tu SM; Chapin BF; Aparicio A; Corn P; Wang J; Subudhi SK; Araujo J; Papadopoulos J; Pruitt L; Weldon JA; Logothetis CJ; Efstathiou E
Eur J Cancer; 2021 Nov; 157():259-267. PubMed ID: 34536949
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular and Thromboembolic Events in Patients With Localized Prostate Cancer Receiving Intensified Neoadjuvant Androgen Deprivation: A Systematic Review and Meta-Analysis.
Felício de Campos E; Xavier CB; Queiroz MM; Firmino Lima Júnior N; Ilario EN; Coelho RF; Nahas WC; Bastos DA; Fontes Jardim DL
Clin Genitourin Cancer; 2024 Jun; 22(3):102088. PubMed ID: 38718699
[TBL] [Abstract][Full Text] [Related]
12. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.
Lee LS; Sim AYL; Ong CW; Yang X; Ng CCY; Liu W; Rajasegaran V; Lim AMS; Aslim EJ; Ngo NT; Khor LY; Kanesvaran R; Allen JCJ; Tay KJ; Yuen JSP; Chong TW; Ho SSH; Teh BT; Chua MLK
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):741-748. PubMed ID: 35091711
[TBL] [Abstract][Full Text] [Related]
13. Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Graham LS; True LD; Gulati R; Schade GR; Wright J; Grivas P; Yezefski T; Nega K; Alexander K; Hou WM; Yu EY; Montgomery B; Mostaghel EA; Matsumoto AA; Marck B; Sharifi N; Ellis WJ; Reder NP; Lin DW; Nelson PS; Schweizer MT
Prostate; 2021 May; 81(7):418-426. PubMed ID: 33755225
[TBL] [Abstract][Full Text] [Related]
14. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.
Koontz BF; Hoffman KE; Halabi S; Healy P; Anand M; George DJ; Harrison MR; Zhang T; Berry WR; Corn PG; Lee WR; Armstrong AJ
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1271-1278. PubMed ID: 33259932
[TBL] [Abstract][Full Text] [Related]
15. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
16. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
17. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
[TBL] [Abstract][Full Text] [Related]
18. Perioperative Morbidity of Radical Prostatectomy After Intensive Neoadjuvant Androgen Blockade in Men With High-Risk Prostate Cancer: Results of Phase II Trial Compared to a Control Group.
Ilario EN; Bastos DA; Guglielmetti GB; Murta CB; Cardili L; Cordeiro MD; Junior JP; Coelho RF; Nahas WC
Clin Genitourin Cancer; 2023 Feb; 21(1):43-54. PubMed ID: 36428171
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
Calagua C; Russo J; Sun Y; Schaefer R; Lis R; Zhang Z; Mahoney K; Bubley GJ; Loda M; Taplin ME; Balk SP; Ye H
Clin Cancer Res; 2017 Nov; 23(22):6812-6822. PubMed ID: 28893901
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
